Call to schedule a consult (828) 761-1710
LifeWay Health is now able to provide Evusheld to patients 12 and older. Evusheld is the only monoclonal antibody developed to provide prophylactic protection from COVID-19.
Evusheld is administered in two intramuscular injections. Below is the eligibility for administration. This may provide 6-12 months of protection from COVID-19.
Evusheld Eligibility Criteria:
Adults and pediatric individuals (12 years of age and older weighing at least 88 pounds 40 kg):
Who are not currently infected with SARS-CoV-2 and who have not had a known recent exposure to an individual infected with SARS-CoV-2, AND:
Who have moderate to severe immune compromise due to a medical condition or receipt of immunosuppressive medications or treatments and may not mount an adequate immune response to COVID-19 vaccination, OR
For whom vaccination with any available COVID-19 vaccine, according to the approved or authorized schedule, is not recommended due to a history of severe adverse reaction (e.g., severe allergic reaction) to a COVID-19 vaccine(s) and/or COVID-19 vaccine component(s).
Moderate to severe immune compromise includes:
Receiving active chemotherapy for any solid tumor malignancy
Hematological malignancy
Solid organ transplant and are taking immunosuppressants
Receipt of CAR-T within 2 years or maintained on immunosuppression
Hematopoietic cell transplant within past 2 years or maintained on immunosuppression or IgG replacement
Primary immunodeficiency
AIDS (CD4 < 200 or 15%)
GVHD receiving immunosuppression
Receiving T- or B- cell compromising drug
Anatomic or functional asplenia
Sickle cell anemia or thalassemia
Aplastic anemia
Stage IV CKD or worse (i.e., requiring renal replacement therapy)
Neutropenia (ANC < 1000)
Myelodysplastic syndrome on therapy
Age ≥65 AND
Nonresponsive antibody assay OR
2 or more impairments of Assisted Daily Living (ADL)
SARS-CoV-2 antibody seronegative after 3 previous vaccines*
All other immunosuppressive conditions receiving immunotherapy**
Comentarios